Skip to main content

Table 1 Patient characteristics of the study population

From: The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial

Characteristic Percentage (%)/Median (range)
Age (years) 62.7 (32–85)
Baseline CA-125 level (U/mL) 725 (14–26,190)
Nadir CA-125 level (U/mL) 10 (6–35)
CA-125 level at relapse (U/mL) 124 (32–5528)
Histology
 High grade Serous 104 (73.2)
 High grade Endometrioid 26 (18.3)
 Undifferentiated 9 (6.3)
Malignant mixed müllerian tumor 3 (2.1)
Surgical residual of initial CRS
 < 1 cm 88 (62.0)
 1–2 cm 5 (3.5)
 > 2 cm 28 (19.7)
 Unknown 21 (14.8)
FIGO stage
 I 10 (7.0)
 II 11 (7.7)
 III 95 (63.6)
 IV 20 (14.1)
 Unknown 6 (4.2)
NAC 92 (63.4)
SNAC 55 (38.7)
BRCA mutations 5 (22.7)
Avastin® at recurrence 44 (31.0)
  1. FIGO the International Federation of Gynecology and Obstetrics, NAC Neo-adjuvant chemotherapy, SNAC Secondary Neo-adjuvant chemotherapy